 | | | | Henry Yeung, a pediatrician and president of the Hong Kong Doctors Union, has just boosted his orders for a popular vaccine for infants - stocking up in preparation for a surge in mainland Chinese visitors spooked by the country's latest vaccine scandal. | | |
| | | A Chinese vaccine scandal has laid bare a new challenge Beijing faces in its long-running battle for information control: blogs and online articles by independent writers capable of unleashing a storm of public fury. | | |
| | | (Reuters Health) - Sexual minorities are less likely to be employed or to have health insurance than their straight peers, a new U.S. study suggests. | | |
| | | (Reuters Health) - Healthy kids with chronically ill siblings may suppress their own needs as they adapt to shifting family dynamics that are focused on caring for the child who is sick, a research review suggests. | | |
| | | (Reuters Health) - Hospitals that switch from paper to electronic health records may eventually see lower death rates than they had before, but a U.S. study also suggests that fatalities may first increase as the transition gets underway. | | |
| | | (Reuters Health) - Office workers who knew that standing during the day could keep them healthier still felt awkward when they stood during meetings while their colleagues were seated, a UK study found. | | |
| | | (Reuters Health) - Plant-derived estrogens, such as those from soy and red clover, might contribute to unwanted weight gain in some postmenopausal women, according to a new review of previous clinical trials. | | |
| | | (Reuters Health) - For women with early-stage breast cancer, many surgeons would advise extensive removal of the lymph nodes under the armpits even though recent evidence shows this doesn't improve survival or the odds of cancer recurring, a U.S. study found. | | |
| | | Britain is to allow doctors to prescribe medicinal cannabis, following a relaxation of the law governing drugs derived from the banned plant. | | |
| | | Bristol-Myers Squibb Co said on Thursday it was told by European regulators that they will recommend against approving the company's drugs Opdivo and Yervoy to treat first-line renal cancer. | | |
| | | AstraZeneca's new drugs performed strongly in the second quarter, offering a glimpse of better times ahead as the company struggles with falling sales of cholesterol fighter Crestor due to generic competition. | | |
|
| |
